Sharekhan

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

What’s Your Call?

Collective community sentiment on Aakaar Medical Technologies Ltd

Your Vote -

Buy

80.00%

Hold

0.00%

Sell

20.00%

80.00%

5 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

NaN%

Sell Order Quantity

NaN%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Aakaar Medical Technologies Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Aakaar Medical Tech - Arrangements for strategic, technical, manufacturing, or marketing tie up

    23 Feb 2026, 5:08PM Aakaar Medical Technologies Limited has informed the Exchange about Arrangements for strategic, technical, manufacturing, or marketing tie up
  • Aakaar Medical Tech - Analysts/Institutional Investor Meet/Con. Call Updates

    23 Feb 2026, 12:03PM Aakaar Medical Technologies Limited has informed the Exchange about Schedule of meet
  • Aakaar Medical Tech - Press Release

    20 Feb 2026, 2:21PM Aakaar Medical Technologies Limited has informed the Exchange regarding a press release dated February 20, 2026, titled ""Strategic Tie-Up with Tricop
  • Aakaar Medical Tech - Press Release

    18 Feb 2026, 12:16PM Aakaar Medical Technologies Limited has informed the Exchange regarding a press release dated February 18, 2026, titled ""Strategic Tie-Up with FotoFi
  • Aakaar Medical Tech - Press Release

    16 Feb 2026, 12:05PM Aakaar Medical Technologies Limited has informed the Exchange regarding a press release dated February 16, 2026, titled ""XOMAGEr Plant Exosomes Regis
  • Aakaar Medical Tech - Press Release

    13 Feb 2026, 12:55PM Aakaar Medical Technologies Limited has informed the Exchange regarding a press release dated February 13, 2026, titled ""USFDA Approval of Sayphar an
  • Aakaar Medical Tech - Arrangements for strategic, technical, manufacturing, or marketing tie up

    12 Feb 2026, 12:55PM Aakaar Medical Technologies Limited has informed the Exchange about Arrangements for strategic, technical, manufacturing, or marketing tie up
  • Aakaar Medical Tech - Product launch

    11 Feb 2026, 6:26PM Aakaar Medical Technologies Limited has informed the Exchange about Product launch
  • Aakaar Medical Tech - Product launch

    11 Feb 2026, 6:24PM Aakaar Medical Technologies Limited has informed the Exchange about VM Corporation Product launch
  • Aakaar Medical Tech - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    8 Jan 2026, 3:00PM In compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, please find attached herewith the certificate issued by

Key fundamentals

Evaluate the intrinsic value of Aakaar Medical Technologies Ltd stock 

Name March-25 March-24
Assets 45.9411 27.5982
Liabilities 45.9411 27.5982
Equity 10.4224 0.7
Gross Profit 9.7369 4.9989
Net Profit 6.0395 2.8702
Cash From Operating Activities -5.4063 -8.0441
NPM(%) 9.8 6.22
Revenue 61.5828 46.111
Expenses 51.8459 41.1121
ROE(%) 12.81 6.08

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Aakaar Medical Technologies Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 648.75 -4.60 38.52 0.00 301.39 0.77
Lotus Eye Hospital and Institute Ltd 107.56 -3.20 346.97 0.00 3.55 0.00
Vaishali Pharma Ltd 6.51 -3.41 0.00 0.00 3.13 0.00
Astec Lifesciences Ltd 625.75 -0.29 0.00 0.00 -604.75 0.00

Company Info

Our Company was originally incorporated as `Aakaar Medical Technologies Private Limited', a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated June 20, 2013 issued by the Registrar of Companies, Mumbai. Subsequently, our Company was converted into a public limited company pursuant to a resolution passed by our shareholders at an extraordinary general meeting held on July 19, 2024 and a fresh certificate of incorporation dated November 18, 2024 was issued by the Registrar of Companies, Mumbai, recording the change in the name of our Company from `Aakaar Medical Technologies Private Limited' to `Aakaar Medical Technologies Limited'.Major Events:2013- Incorporated as Aakaar Medical Technologies Private Limited.2016- Entered into licensing, marketing and distribution agreement with Medytox Inc., South Korea for launch of Siax.2017- Launched our own brands Tubelite.- Launched our own brand Balback.- Launched our own brand Lytec.2018-Entered into a tripartite agreement with ACPL and Croma Pharma GmbH for launch of Saypha filler (earlier known as Princess).2022- Launched our own brand Etrelume.2023- Launched our own brand Swyada.- Entered into exclusive agreement in licensing, marketing and distribution with Regenera Activa Worldwide S.L for launch of Regenera ActivaAMT.- Entered into exclusive agreement in licensing, marketing and distribution with Tesslift Co. Limited.2024- Launched our own brand Exoluxe and DRS1512.- Launched our Own brand Eoluxe.- Conversion of our Company from a private limited company to a public limited company.

Our Company was originally incorporated as `Aakaar Medical Technologies Private Limited', a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated June 20, 2013 issued by the Registrar of Companies, Mumbai. Subsequently, our Company was converted into a public limited company pursuant to a resolution passed by our shareholders at an extraordinary general meeting held on July 19, 2024 and a fresh certificate of incorporation dated November 18, 2024 was issued by the Registrar of Companies, Mumbai, recording the change in the name of our Company from `Aakaar Medical Technologies Private Limited' to `Aakaar Medical Technologies Limited'.Major Events:2013- Incorporated as Aakaar Medical Technologies Private Limited.2016- Entered into licensing, marketing and distribution agreement with Medytox Inc., South Korea for launch of Siax.2017- Launched our own brands Tubelite.- Launched our own brand Balback.- Launched our own brand Lytec.2018-Entered into a tripartite agreement with ACPL and Croma Pharma GmbH for launch of Saypha filler (earlier known as Princess).2022- Launched our own brand Etrelume.2023- Launched our own brand Swyada.- Entered into exclusive agreement in licensing, marketing and distribution with Regenera Activa Worldwide S.L for launch of Regenera ActivaAMT.- Entered into exclusive agreement in licensing, marketing and distribution with Tesslift Co. Limited.2024- Launched our own brand Exoluxe and DRS1512.- Launched our Own brand Eoluxe.- Conversion of our Company from a private limited company to a public limited company.

Read More

Parent Organisation

Aakaar Medical Technologies Ltd.

Founded

20/06/2013

Managing Director

Mr.Rahul Babasaheb Sawakhande

NSE Symbol

AAKAARSM

FAQ

The current price of Aakaar Medical Technologies Ltd is

The 52-week high for Aakaar Medical Technologies Ltd is

The market capitalization of Aakaar Medical Technologies Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Aakaar Medical Technologies Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Aakaar Medical Technologies Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Aakaar Medical Technologies Ltd shares.

The CEO of Aakaar Medical Technologies Ltd is Mr.Rahul Babasaheb Sawakhande, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT